Asset Details
Do you wish to reserve the book?
AB0972 EFFICACY OF TILDRAKIZUMAB IN PATIENTS WITH PSORIASIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
AB0972 EFFICACY OF TILDRAKIZUMAB IN PATIENTS WITH PSORIASIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Do you wish to request the book?
AB0972 EFFICACY OF TILDRAKIZUMAB IN PATIENTS WITH PSORIASIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
AB0972 EFFICACY OF TILDRAKIZUMAB IN PATIENTS WITH PSORIASIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
2023
Overview
BackgroundPsoriasis is a common chronic inflammatory disease of the skin[1]. The IL-23/IL-17 immune pathway plays a vital role in promoting Psoriasis pathogenesis[2]. Tildrakizumab, a humanized IgG1 monoclonal antibody against interleukin 23 p19, is currently used in the treatment of patients with psoriasis.ObjectivesThis study aimed to evaluate the efficacy of tildrakizumab in the treatment of psoriasis.MethodsFive databases, including PubMed, Embase, Medline, Web of Science, and Cochrane Library, were retrieved from their establishment to January 2, 2023. We used the EndNote X9 software to filter the retrieved articles according to the inclusion and exclusion criteria. Heterogeneity was tested using I-squared (I2). When I2>50%, we choosed the random effects model for data analysis, conversely, a fixed effects model. Publication bias was assessed using the Egger test. All analyzes were performed in STATA 12.0.ResultsWe included 6 studies, 2,395 patients in the Tildrakizumab group and 552 patients in the placebo group (Table 1). Results of the meta-analysis showed that 68% of patients with psoriasis met the PAIS75 remission criteria after taking Tildrakizumab [Rate =0.68 95%CI(0.66, 0.70), P<0.001], and they had significantly higher PASI75 response rates than the placebo group [RR=11.390, 95%CI (8.08, 16.06), P<0.001]. Compared to the placebo group, patients in the Tildrakizumab group had a significantly higher remission rate of PASI90 [RR=26.751, 95%CI (15.282,46.827), P<0.001]. In addition, patients taking Tildrakizumab had an average 15-point reduction in PASI scores [Rate=-14.854 95%CI(-19.146, -10.561), P<0.001], and 45% of patients achieved PASI100 remission criteria [Rate= 0.450, 95%CI (0.131, 0.769), P=0.006] (Figure 1).ConclusionThis study showed that Tildrakizumab improved disease activity and increased clinical remission rates in patients with psoriasis, demonstrating a better therapeutic effect.References[1]Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet 2021; 397 (10281): 1301-1315. doi: 10.1016/s0140-6736(20)32549-6.[2]Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol 2018; 55 (3): 379-390. doi: 10.1007/s12016-018-8702-3.Table 1.Population characteristics included in the studyAuthor(Year)Population (include in analysis)Age (Mean±SD)Gender (male %)TILPBOTILPBOTILPBOKristian Reich(2017)617(617)155(154)46.65±13.1447.9±13.570.264.5K. Papp(2015)309(102)46(41)44.79±13.0445.9±11.775.182.5Alessandra Narcisi.(2022)237(121)NA48.6±14.6NA59.9NAY Poulin(2020)1413(1413)357(357)NA72.170.0Cantrell, W.(2021)248(135)NANANAT Graier(2022)15(7)NA45.9±14.1NA73.3NAAcknowledgements:NIL.Disclosure of InterestsNone Declared.
